Literature DB >> 1894371

Specific and nonspecific antibody responses in different segments of the respiratory tract in rats infected with Mycoplasma pulmonis.

J W Simecka1, P Patel, J K Davis, S E Ross, P Otwell, G H Cassell.   

Abstract

Murine respiratory mycoplasmosis resulting from Mycoplasma pulmonis infection in rats provides a useful model for the study of immunological and inflammatory mechanisms operative in the respiratory tract. We have previously shown that LEW rats develop more severe disease than do F344 rats. To further study the production of antibody responses in chronic respiratory disease due to M. pulmonis infection, we examined the distribution and development of M. pulmonis-specific antibody-forming cells (AFC) in different segments of the respiratory tracts of infected LEW and F344 rats. In these studies, the upper respiratory nodes were the initial site of antibody production after infection and remained the major site for recovery of AFC. Since infected LEW rats had equal or higher numbers of AFC than did infected F344 rats, these results suggest that the level of local antibody production alone is not responsible for the decreased susceptibility of F344 rats to murine respiratory mycoplasmosis. The differences in total antibody responses appear to be due to the greater numbers of cells recovered from the tissues of infected LEW rats compared with those recovered from F344 rats, suggesting that LEW rats may have greater production of chemotactic factors. Also, we demonstrate that nonspecific activation and/or recruitment of B cells occurs in the respiratory tracts of both LEW and F344 rats after infection with M. pulmonis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1894371      PMCID: PMC258943          DOI: 10.1128/iai.59.10.3715-3721.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  Comparison of enzyme-linked immunosorbent assay and radioimmunoprecipitation test for detection of immunoglobulin A antibodies to Mycoplasma pneumoniae in nasal secretions.

Authors:  Y Naot; E Lis; R Siman-Tov; H Brunner
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

2.  Nonspecific lymphocyte responses in F344 and LEW rats: susceptibility to murine respiratory mycoplasmosis and examination of cellular basis for strain differences.

Authors:  J K Davis; J W Simecka; J S Williamson; S E Ross; M M Juliana; R B Thorp; G H Cassell
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

3.  Immunofluorescent procedures for mycoplasma identification.

Authors:  R A Del Guidice; M F Barile
Journal:  Dev Biol Stand       Date:  1974

4.  Tissue cultures and mycoplasmas.

Authors:  L Hayflick
Journal:  Tex Rep Biol Med       Date:  1965-06

5.  Activation of B lymphocytes by mycoplasma mitogen(s).

Authors:  Y Naot; H Ginsburg
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

6.  IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release.

Authors:  T A Platts-Mills; R K von Maur; K Ishizaka; P S Norman; L M Lichtenstein
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

7.  Class-specific antibody responses to Mycoplasma pulmonis in sera and lungs of infected and vaccinated mice.

Authors:  G Taylor; C J Howard
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

8.  Protective effect of vaccination against Mycoplasma pulmonis respiratory disease in rats.

Authors:  G H Cassell; J K Davis
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

9.  Upper respiratory tract is the major site of antibody production in mycoplasmal induced chronic respiratory disease.

Authors:  J W Simecka; P Patel; J K Davis; G H Cassell
Journal:  Reg Immunol       Date:  1989 Nov-Dec

10.  Formation of secretory and circulating antibodies after immunization with live and inactivated influenza virus vaccines.

Authors:  Y S Shvartsman; E N Agranovskaya; M P Zykov
Journal:  J Infect Dis       Date:  1977-05       Impact factor: 5.226

View more
  7 in total

1.  Gene rearrangements in the vsa locus of Mycoplasma pulmonis.

Authors:  X Shen; J Gumulak; H Yu; C T French; N Zou; K Dybvig
Journal:  J Bacteriol       Date:  2000-05       Impact factor: 3.490

2.  Number of specific antibody-secreting cells in the peripheral blood among children with mycoplasma pneumonia.

Authors:  M Iseki; T Takahashi; K Kimura; R Yamashita; T Sasaki
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  THE MULTIFACETED ROLE OF T CELL-MEDIATED IMMUNITY IN PATHOGENESIS AND RESISTANCE TO MYCOPLASMA RESPIRATORY DISEASE.

Authors:  Nicole A Dobbs; Adam N Odeh; Xiangle Sun; Jerry W Simecka
Journal:  Curr Trends Immunol       Date:  2009

4.  Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization.

Authors:  L M Hodge; M Marinaro; H P Jones; J R McGhee; H Kiyono; J W Simecka
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

5.  Lung and splenic B cells facilitate diverse effects on in vitro measures of antitumor immune responses.

Authors:  Harlan P Jones; Yi-Chong Wang; Beau Aldridge; Jay M Weiss
Journal:  Cancer Immun       Date:  2008-02-19

6.  Chronic pulmonary infection caused by Mycoplasma pneumoniae leading to pulmonary arteriole remodeling and pulmonary hypertension in rats.

Authors:  D X Liu; D X Peng; R Chen; H T Lei; D Y Che; S Y Zhao
Journal:  J Tongji Med Univ       Date:  1995

7.  The Use of Bacteriophages and Immunological Monitoring for the Treatment of a Case of Chronic Septicemic Cutaneous Ulcerative Disease in a Loggerhead Sea Turtle Caretta caretta.

Authors:  Whitney Greene; Benjamin Chan; Erin Bromage; Julianne H Grose; Cathy Walsh; Kaitlyn Kortright; Sue Forrest; Grace Perry; Lynne Byrd; M Andrew Stamper
Journal:  J Aquat Anim Health       Date:  2021-07-02       Impact factor: 1.625

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.